Royalty Pharma Q3: Net Income Halved to $145M on Pelacarsen Impairment; Vertex Royalty Dispute Disclosed
RPRX sits 84% above its 52-week low of $36.027.
Summary
Royalty Pharma's Q3 revenue rose 13% to $690M and cash flow improved, but GAAP net income fell to $145M on a $150.4M pelacarsen impairment. The 10-Q also discloses a formal royalty dispute with Vertex over Alyftrek payments.
Key Events · Earnings and Guidance · RPRX
-
Q3 Revenue Up 13%, Earnings Halved
Total income and other revenues rose to $690.1M from $609.3M, but net income attributable to Royalty Pharma fell to $144.7M ($0.32 per share) from $284.2M ($0.66) a year earlier.
-
$150.4M Pelacarsen Impairment
Non-cash impairment charges totaled $219.8M for the first nine months, including $150.4M on pelacarsen after Novartis' Phase 3 trial missed its primary endpoint and $69.4M on Tazverik after its voluntary withdrawal.
-
Vertex Alyftrek Royalty Dispute
Since Q2 2025 Royalty Pharma has not received the full Alyftrek royalty it believes it is contractually owed and has commenced the agreements' dispute resolution procedures; any recovery is recognized only if resolved in its favor.
-
Cash Flow and Balance Sheet Strengthen
Nine-month operating cash flow rose to $2.13B from $1.66B; the $380M term loan was repaid in July 2026 and a new $1.8B revolver maturing 2031 is undrawn.
Analysis · RPRX · Life Sciences
Revenue grew 13% to $690M and cash generation improved, but GAAP earnings fell by half because of a $150.4M non-cash write-down on pelacarsen after Novartis' Phase 3 Lp(a)HORIZON trial missed its primary endpoint, plus a jump in share-based compensation tied to the 2025 internalization. The bigger new item is the disclosure that since Q2 2025 Royalty Pharma has not received the full Alyftrek royalty it believes it is owed from Vertex and has started formal dispute resolution — Vertex's cystic fibrosis franchise is the single largest royalty asset at $4.76B gross carrying value and 31% of Q3 revenue, so any adverse outcome would hit the core of the portfolio. Offsetting that, nine-month operating cash flow rose to $2.13B from $1.66B, the $380M term loan was repaid, and the company has a fresh $1.8B revolver with no draws.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RPRX was trading at $66.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $36.03 to $67.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.